Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

954 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Fasting and cancer treatment in humans: A case series report.
Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Safdie FM, et al. Among authors: quinn d. Aging (Albany NY). 2009 Dec 31;1(12):988-1007. doi: 10.18632/aging.100114. Aging (Albany NY). 2009. PMID: 20157582 Free PMC article.
Molecular markers of prostate cancer outcome.
Quinn DI, Henshall SM, Sutherland RL. Quinn DI, et al. Eur J Cancer. 2005 Apr;41(6):858-87. doi: 10.1016/j.ejca.2004.12.035. Eur J Cancer. 2005. PMID: 15808955 Review.
EphB4 expression and biological significance in prostate cancer.
Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. Xia G, et al. Among authors: quinn di. Cancer Res. 2005 Jun 1;65(11):4623-32. doi: 10.1158/0008-5472.CAN-04-2667. Cancer Res. 2005. PMID: 15930280
Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
Raghavan D, Brandes LJ, Klapp K, Snyder T, Styles E, Tsao-Wei D, Lieskovsky G, Quinn DI, Ramsey EW. Raghavan D, et al. Among authors: quinn di. J Urol. 2005 Nov;174(5):1808-13; discussion 1813. doi: 10.1097/01.ju.0000176799.63184.99. J Urol. 2005. PMID: 16217292 Clinical Trial.
Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.
Levine AM, Tulpule A, Quinn DI, Gorospe G 3rd, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. Levine AM, et al. Among authors: quinn di. J Clin Oncol. 2006 Apr 10;24(11):1712-9. doi: 10.1200/JCO.2005.03.4801. Epub 2006 Mar 6. J Clin Oncol. 2006. PMID: 16520466 Clinical Trial.
954 results